Difference between revisions of "Fred Hutchinson Cancer Center patent applications published on March 21st, 2024"
Wikipatents (talk | contribs) |
Wikipatents (talk | contribs) |
(One intermediate revision by the same user not shown) | |
(No difference)
|
Latest revision as of 08:28, 27 March 2024
Summary of the patent applications from Fred Hutchinson Cancer Center on March 21st, 2024
The Fred Hutchinson Cancer Center has recently filed patents related to markers, methods, and systems for identifying cell populations, diagnosing, monitoring, and treating cancer, with a focus on biomarkers predictive of response to immunotherapy treatment in Merkel cell carcinoma. Additionally, they have filed patents for single-domain antibodies that bind receptor tyrosine kinase (ROR1) for various applications, as well as Delta-like non-canonical Notch ligand 1 (DLK1) inhibitors for the treatment of various cancers. They have also filed a patent for an anti-Epstein Barr Virus (EBV) vaccine to treat and reduce the risk of EBV infection and associated complications.
Notable applications:
- Precision medicine for cancer treatment
- Development of personalized immunotherapy strategies
- Treatment of myelodysplastic syndrome (MDS)
- Development of vaccines for preventing EBV infection and its associated complications.
Contents
- 1 Patent applications for Fred Hutchinson Cancer Center on March 21st, 2024
- 1.1 CHIMERIC ANTIGEN RECEPTORS THAT BIND PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME)/HLA-A2 TO TREAT CANCER (18454684)
- 1.2 LUTEINIZING HORMONE RECEPTOR BINDING AGENTS AND LUTEINIZING HORMONE AGONISTS TO IDENTIFY, EXPAND, ABLATE AND MODIFY STEM CELLS (18208490)
- 1.3 EPSTEIN BARR VIRUS VACCINES (18458108)
- 1.4 DELTA-LIKE NON-CANONICAL NOTCH LIGAND 1 ACTIVITY MODULATORS AND USES THEREOF (18456339)
- 1.5 SINGLE-DOMAIN ANTIBODIES THAT BIND ROR1 (18350617)
- 1.6 MARKERS, METHODS AND SYSTEMS FOR IDENTIFYING CELL POPULATIONS, DIAGNOSING, MONITORING, PREDICTING AND TREATING CONDITIONS (18509663)
Patent applications for Fred Hutchinson Cancer Center on March 21st, 2024
CHIMERIC ANTIGEN RECEPTORS THAT BIND PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME)/HLA-A2 TO TREAT CANCER (18454684)
Main Inventor
Soheil Meshinchi
LUTEINIZING HORMONE RECEPTOR BINDING AGENTS AND LUTEINIZING HORMONE AGONISTS TO IDENTIFY, EXPAND, ABLATE AND MODIFY STEM CELLS (18208490)
Main Inventor
Jarrod Dudakov
EPSTEIN BARR VIRUS VACCINES (18458108)
Main Inventor
Jason Price
DELTA-LIKE NON-CANONICAL NOTCH LIGAND 1 ACTIVITY MODULATORS AND USES THEREOF (18456339)
Main Inventor
Irwin D. Bernstein
SINGLE-DOMAIN ANTIBODIES THAT BIND ROR1 (18350617)
Main Inventor
Jason Price
MARKERS, METHODS AND SYSTEMS FOR IDENTIFYING CELL POPULATIONS, DIAGNOSING, MONITORING, PREDICTING AND TREATING CONDITIONS (18509663)
Main Inventor
Evan Greene